March 25, 2010
Xifaxan 550mg approved to reduce risk of hepatic encephalopathy
Xifaxan 550mg is expected to be available by the end of May 2010. Xifaxan is already available in a 200mg dosage strength tablet indicated for the treatment of traveler's diarrhea due to noninvasive Escherichia coli.
For more information call (800) 508-0024 or visit www.salix.com.